Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/11/2025

Target INR for Patients with Ischemic Stroke and Patent Foramen Ovale

Introduction to Target INR

  • The American College of Cardiology recommends a target INR of 2.0 to 3.0, with an ideal value of 2.5, for patients with ischemic stroke and patent foramen ovale (PFO) during warfarin treatment (Class IIa, Level of Evidence B) 1

Recomendações Específicas para FOP e AVC

  • For patients with ischemic stroke or transient ischemic attack (TIA) and a PFO, antiplatelet therapy is reasonable to prevent recurrent events (Class IIa, Level of Evidence B) 1
  • Warfarin is reasonable for high-risk patients who have other indications for oral anticoagulation, such as those with an underlying hypercoagulable state or evidence of venous thrombosis (Class IIa, Level of Evidence C) 1
  • When warfarin is used for secondary prevention in patients with PFO and cryptogenic stroke, the target INR should be maintained between 2.0 and 3.0 1, 2

Evidências de Eficácia

  • In the PICSS (Patent Foramen Ovale in Cryptogenic Stroke Study), patients with cryptogenic stroke and PFO treated with warfarin (target INR of 1.4 to 2.8) had an event rate of 9.5%, compared with 17.9% in those treated with aspirin, although this difference was not statistically significant (HR 0.52; 95% CI, 0.16 to 1.67; P=0.28) 1
  • Cujec et al. analyzed a cohort of 90 patients with cryptogenic stroke aged <60 years, more than half of whom had PFO, and reported that warfarin was more effective than antiplatelet therapy for secondary prevention of stroke 1

Monitoramento do INR

  • The American College of Cardiology recommends that the INR be determined at least weekly during the initiation of anticoagulant therapy 3, 2
  • Once anticoagulation is stable (INR consistently within the therapeutic range), monitoring can be reduced to at least monthly 3, 2
  • Patients should aim for a time in therapeutic range (TTR) >65% to ensure ideal protection against recurrent stroke 2

Riscos e Precauções

  • An INR below 2.0 increases the risk of thromboembolism and recurrent ischemic stroke 2
  • The risk of intracranial hemorrhage increases significantly when the INR exceeds 3.5 2, 4
  • Elderly patients (>65 years) have a higher risk of bleeding at any INR level and may require more cautious management 4
  • Excessive dose reductions (more than 20%) can lead to subtherapeutic INR and increased risk of stroke 4